Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.44 |
| ▸ | CNR2 | P34972 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25849269 | 1.00 | CNR1 (0.44) | CNR1CNR2ALDH1A1TRPV1 | |
| SCHEMBL14617186 | 0.98 | ALDH1A1 (0.45) | CNR1CNR2ALDH1A1TRPV1 | |
| SCHEMBL129691 | 0.98 | ALDH1A1 (0.45) | CNR1CNR2ALDH1A1TRPV1 | |
| SCHEMBL14617185 | 0.98 | ALDH1A1 (0.45) | CNR1CNR2ALDH1A1TRPV1 | |
| SCHEMBL130742 | 0.98 | ALDH1A1 (0.45) | CNR1CNR2ALDH1A1TRPV1 | |
| SCHEMBL16359217 | 0.94 | LPAR2 (0.44) | TRPV1 | |
| SCHEMBL129695 | 0.92 | CNR1 (0.40) | CNR1CNR2ALDH1A1TRPV1 | |
| SCHEMBL131835 | 0.92 | CNR1 (0.40) | CNR1CNR2ALDH1A1TRPV1 | |
| SCHEMBL129777 | 0.90 | ALDH1A1 (0.41) | CNR1CNR2ALDH1A1 | |
| SCHEMBL25849270 | 0.90 | ALDH1A1 (0.41) | CNR1CNR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180125985-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125985-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, LCAT, NPC1L1 | CNR1 1857/4885CNR2 1808/4885ALDH1A1 3880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.